PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsIopamidol
Iopamidol
Iopamidol, Isovue (iopamidol) is a small molecule pharmaceutical. Iopamidol was first approved as Isovue-m 200 on 1985-12-31.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Iopamidol, Isovue (discontinued: Iopamidol, Isovue)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Iopamidol
Tradename
Company
Number
Date
Products
ISOVUE-M 200Bracco DiagnosticsN-018735 RX1985-12-31
1 products, RLD, RS
ISOVUE-300Bracco DiagnosticsN-018735 RX1985-12-31
1 products, RLD, RS
ISOVUE-370Bracco DiagnosticsN-018735 RX1985-12-31
1 products, RLD, RS
ISOVUE-M 300Bracco DiagnosticsN-018735 RX1985-12-31
1 products, RLD, RS
ISOVUE-200Bracco DiagnosticsN-018735 RX1987-07-07
1 products, RLD, RS
ISOVUE-250Bracco DiagnosticsN-018735 RX1992-07-06
1 products, RLD, RS
ISOVUE-300Bracco DiagnosticsN-020327 RX1994-10-12
1 products, RLD, RS
ISOVUE-370Bracco DiagnosticsN-020327 RX1994-10-12
1 products, RLD, RS
Show 3 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
iopamidolANDA2026-07-23
isovueNew Drug Application2026-03-10
isovue-mNew Drug Application2026-02-10
isovue-m 200New Drug Application2017-01-17
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
— V08: Contrast media
— V08A: X-ray contrast media, iodinated
— V08AB: Watersoluble, nephrotropic, low osmolar x-ray contrast media
— V08AB04: Iopamidol
HCPCS
No data
Clinical
Clinical Trials
52 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Kidney diseasesD007674EFO_0003086N08——1225
Coronary artery diseaseD003324—I25.1—1—135
Renal insufficiencyD051437—N19—113—5
Chronic renal insufficiencyD051436—N18—1—214
Coronary stenosisD023921EFO_1000882————3—3
Diabetes mellitusD003920EFO_0000400E08-E13—1—2—3
Chronic painD059350—————112
Body weightD001835EFO_0004338————2—2
Acute kidney injuryD058186—N17——11—2
Healthy volunteers/patients———11—1—2
Show 10 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver neoplasmsD008113EFO_1001513C22.0—11—13
CarcinomaD002277—C80.01—1—13
Hepatocellular carcinomaD006528—C22.0——1—12
Computed tomography angiographyD000072226————1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C8011———2
Neoplasm metastasisD009362EFO_0009708——1——12
Knee osteoarthritisD020370EFO_0004616M17—1———1
OsteoarthritisD010003EFO_0002506M15-M19—1———1
Heart failureD006333EFO_0003144I50—1———1
Pancreatic neoplasmsD010190EFO_0003860C25—1———1
Duodenal neoplasmsD004379———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C502———13
Triple negative breast neoplasmsD064726——1————1
Renal cell carcinomaD002292EFO_0000376—1————1
Castration-resistant prostatic neoplasmsD064129——1————1
Urologic neoplasmsD014571—C64-C681————1
Non-small-cell lung carcinomaD002289——1————1
Lung neoplasmsD008175—C34.901————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myocardial ischemiaD017202EFO_1001375I20-I25————33
Coronary diseaseD003327——————22
IschemiaD007511EFO_0000556—————11
Intraoperative complicationsD007431——————11
Postoperative complicationsD011183——————11
GallstonesD042882EFO_0004210—————11
Laparoscopic cholecystectomyD017081——————11
CholelithiasisD002769EFO_0004799K80————11
CholecystolithiasisD041761EFO_1000864—————11
Biliary tract diseasesD001660EFO_0009534K83.9————11
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIopamidol
INNiopamidol
Description
Iopamidol is a benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position. It has a role as a radioopaque medium, an environmental contaminant and a xenobiotic. It is a benzenedicarboxamide, an organoiodine compound and a pentol.
Classification
Small molecule
Drug classiodine-containing contrast media
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I
Identifiers
PDB—
CAS-ID60166-93-0
RxCUI—
ChEMBL IDCHEMBL1200932
ChEBI ID31711
PubChem CID65492
DrugBankDB08947
UNII IDJR13W81H44 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 4,895 documents
View more details
Safety
Black-box Warning
Black-box warning for: Isovue
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
4,388 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use